162 related articles for article (PubMed ID: 20347502)
1. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Bhoori S; Toffanin S; Sposito C; Germini A; Pellegrinelli A; Lampis A; Mazzaferro V
J Hepatol; 2010 May; 52(5):771-5. PubMed ID: 20347502
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
4. [Hepatocellular carcinoma: what's new?].
Teufel A; Marquardt JU; Galle PR; Wörns M
Dtsch Med Wochenschr; 2012 Feb; 137(5):210-3. PubMed ID: 22250042
[No Abstract] [Full Text] [Related]
5. Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.
Bathaix F; Marion D; Cuinet M; Maillard E; Zoulim F; Mornex F; Merle P
Gastroenterol Clin Biol; 2010; 34(4-5):314-8. PubMed ID: 20207091
[TBL] [Abstract][Full Text] [Related]
6. Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Di Benedetto F; Berretta M; De Ruvo N; Tarantino G; D'Amico G; Ballarin R; Iemmolo RM; Gerunda GE
J Surg Oncol; 2012 Jan; 105(1):111-2. PubMed ID: 21792942
[No Abstract] [Full Text] [Related]
7. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
10. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
11. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
[TBL] [Abstract][Full Text] [Related]
15. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Wakabayashi G
Transplant Proc; 2011 Sep; 43(7):2800-5. PubMed ID: 21911167
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
[TBL] [Abstract][Full Text] [Related]
17. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma.
Harnois DM; Steers J; Andrews JC; Rubin JC; Pitot HC; Burgart L; Wiesner RH; Gores GJ
Liver Transpl Surg; 1999 May; 5(3):192-9. PubMed ID: 10226109
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of hepatocellular carcinoma and molecular therapies.
Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the treatment response of HCC.
Kim KW; Lee JM; Choi BI
Abdom Imaging; 2011 Jun; 36(3):300-14. PubMed ID: 21279353
[TBL] [Abstract][Full Text] [Related]
20. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
